

(19) **DANMARK**

(10) **DK/EP 2193788 T3**



(12) **Oversættelse af  
europæisk patentskrift**

Patent- og  
Varemærkestyrelsen

- 
- (51) Int.Cl.: **A 61 K 9/20 (2006.01)** **A 61 K 9/00 (2006.01)** **A 61 K 9/14 (2006.01)**  
**A 61 K 31/435 (2006.01)** **A 61 K 31/445 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2016-02-01**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2015-10-21**
- (86) Europæisk ansøgning nr.: **09177889.4**
- (86) Europæisk indleveringsdag: **2002-09-27**
- (87) Den europæiske ansøgnings publiceringsdag: **2010-06-09**
- (30) Prioritet: **2001-09-28 GB 0123400**
- (62) Stamansøgningsnr: **02774661.9**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR**
- (73) Patenthaver: **Novartis AG, Lichtstrasse 35, 4056 Basel, Schweiz**
- (72) Opfinder: **Haeberlin, Barbara, Binningerstrasse 5, 4142, Münchenstein, Schweiz**  
**Kramer, Andrea, Bündte 7, 5027, Herznach, Schweiz**  
**Heuerding, Silvia, Rütlistrasse 2, 4051, Basel, Schweiz**
- (74) Fuldmægtig i Danmark: **Marks & Clerk (Luxembourg) LLP, 44 rue de la Vallée, B.P. 1775, L-1017 Luxembourg, Luxembourg**
- (54) Benævnelse: **FARMACEUTISKE SAMMENSÆTNINGER OMFATTENDE KOLLOIDT SILICIUMDIOXID**
- (56) Fremdragne publikationer:  
**EP-A- 1 145 711**  
**US-A- 6 004 973**  
**NÜRNBERG E ET AL: "Coating of cellulose products with colloidal silicon dioxide. Investigations to improve tableting behaviour using low dose tablets as an example" DRUGS MADE IN GERMANY, AULENDORF, DE, vol. 39, no. 3, 1996, pages 104-107, XP002902513 ISSN: 0012-6682**  
**LINDEN R ET AL: "Response surface analysis applied to the preparation of tablets containing a high concentration of vegetable spray-dried extract." DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY. UNITED STATES APR 2000, vol. 26, no. 4, April 2000 (2000-04), pages 441-446, XP009006020 ISSN: 0363-9045**  
**WAN L S C ET AL: "A MULTIPLE-UNIT TABLET FORMULATION FOR MULTI-LAYER DRUG-COATED GRANULES" SCIENCES TECHNIQUES ET PRATIQUES STP PHARMA SCIENCES, PARIS, FR, vol. 4, no. 5, 1 January 1994 (1994-01-01) , pages 336-342, XP009006010 ISSN: 1157-1489**



## DESCRIPTION

**[0001]** This invention relates to novel oral pharmaceutical compositions comprising a macrolide, e.g. rapamycin or a derivative thereof or an ascomycin, in a solid dispersion.

**[0002]** The term "macrolide" as used herein, refers to a macrocyclic lactone, for example a compound having a 12- membered or larger lactone ring. Of particular interest are the "lactam macrolides", i.e., macrocyclic compounds having a lactam (amide) bond in the macrocycle in addition to a lactone (ester) bond, for example the lactam macrolides produced by microorganisms of the genus *Streptomyces* such as rapamycin, ascomycin, and FK-506, and their numerous derivatives and analogues. Such lactam macrolides have been shown to have interesting pharmaceutical properties, particularly immunosuppressive and anti-inflammatory properties.

**[0003]** Rapamycin is an immunosuppressive lactam macrolide that is produced by *Streptomyces hygroscopicus*. The structure of rapamycin is given in Kessler, H., et al.; 1993; *Helv. Chim. Acta*; 76: 117. See, e.g., McAlpine, J.B., et al., *J. Antibiotics* (1991) 44: 688; Schreiber, S.L., et al., *J. Am. Chem. Soc.* (1991) 113: 7433; US Patent No. 3 929 992. Rapamycin is an extremely potent immunosuppressant and has also been shown to have antitumor and antifungal activity. Its utility as a pharmaceutical, however, is restricted by its very low and variable bioavailability. Moreover, rapamycin is highly insoluble in aqueous media, e.g. water, making it difficult to formulate galenic compositions. Numerous derivatives of rapamycin are known. Certain 16-O-substituted rapamycin derivatives are disclosed in WO 94/02136. 40-O-substituted rapamycin derivatives are described in, e.g., US 5 258 389 and WO 94/09010 (O-aryl and O-alkyl rapamycin derivatives); WO 92/05179 (carboxylic acid esters), US 5 118 677 (amide esters), US 5 118 678 (carbamates), US 5 100 883 (fluorinated esters), US 5 151 413 (acetals), US 5 120 842 (silyl ethers), WO 93/11130 (methylene rapamycin and derivatives), WO 94/02136 (methoxy derivatives), WO 94/02385 and WO 95/14023 (alkenyl derivatives). 32-O-dihydro or substituted rapamycin derivatives are described, e.g., in US 5 256 790.

**[0004]** Further rapamycin derivatives are described in PCT international application WO96/02441, for example 32-deoxorapamycin is described in Example 1, and 16-pent-2-ynyloxy-32(S)-dihydrorapamycin is described in Examples 2 and 3.

**[0005]** On oral administration to humans, solid rapamycin or rapamycin derivatives, may not be absorbed to any significant extent into the bloodstream. PCT application WO 97/03654, describes pharmaceutical compositions in the form of a solid dispersion comprising a macrolide, e.g. a rapamycin, ascomycin or a derivative thereof, and a carrier medium. These compositions provide improved bioavailability of drug substance, are convenient to administer, and are stable.

**[0006]** However for certain groups of patients, oral administration of medicaments in solid tablet form is either undesirable or impractical. In particular, children and elderly patients may be unable to swallow such tablets conveniently. For these patients, it is typically more desirable to provide a tablet which can first be dispersed in an ingestible liquid, before consumption by the patient.

**[0007]** For administration to children and elderly patients, it would be highly desirable to provide a tablet which disperses rapidly in an ingestible liquid such as water. A problem with the prior art macrolide formulations is that, because they do not necessarily disperse rapidly in aqueous solutions, it may be inconvenient and time-consuming to prepare a sufficiently dispersed liquid preparation before administration to the patient. One particular difficulty in the formulation of a macrolide solid dispersion composition in the form of a dispersible tablet is the high amount of carrier used in solid dispersion compositions, acting as a binder in tablet formulations.

**[0008]** It is known that a more rapidly disintegrating tablet can be produced by using a lower compaction force during the tablet manufacturing process. However, this typically results in a tablet which has inferior mechanical properties. In particular, weakly compressed tablets show insufficient hardness and are liable to crumble, chip or disintegrate before this is desired (i.e. during packaging, transit, storage or at any time before addition of the tablet to an ingestible liquid for consumption).

**[0009]** The present disclosure aims to provide a pharmaceutical composition which alleviates the problems of the prior art compositions. Accordingly, the present invention provides a pharmaceutical composition as defined in claims 1 to 5.

**[0010]** The present disclosure is based on the surprising finding that a particularly rapidly-dispersing composition comprising a macrolide solid dispersion can be provided by using colloidal silicon dioxide to promote disintegration. Colloidal silicon dioxide is known from the prior art primarily as a lubricant or flow-regulating agent in pharmaceutical compositions. Where it is used for such purposes, silicon dioxide typically comprises around 0.5% by weight of the composition. According to the present invention, the inclusion of 1 to 5% by weight of colloidal silicon dioxide has been found to be particularly effective in promoting disintegration of a macrolide solid dispersion in an aqueous solution, when combined with another disintegrant.

**[0011]** Furthermore, the compositions of the present disclosure show high stability and physical integrity, e.g. during storage, handling, packaging and the like, without limiting the disintegration performance of the composition. The inclusion of colloidal silicon dioxide in a suitable amount is additionally advantageous because it results in a composition which, when compressed into a tablet, possesses enhanced mechanical properties. In particular, tablets formed according to the present disclosure possess a surprising combination of rapid disintegration in aqueous solutions with mechanical stability. For a given level of hardness, the inclusion of silicon dioxide results in tablets having a faster disintegration rate. Alternatively, for a given disintegration rate, silicon dioxide containing tablets according to the present invention are harder than tablets which do not contain silicon dioxide.

**[0012]** The compositions of the present disclosure comprise one or more disintegrants. Examples of disintegrants include crosslinked polyvinylpyrrolidone, e.g. as commercially available as Crospovidone® or Polyplasdone® (Handbook of Excipients, p. 143-144) available from ISP; sodium starch glycolate available from Generichem; and crosscarmellose sodium, e.g. as commercially available as Ac-di-sol® from FMC Corporation. Preferably the disintegrant comprises crosslinked polyvinylpyrrolidone.

Crospovidone® is preferably included in the composition of this disclosure in an amount of up to about 50 % by weight, e.g. 10 to 30 %, more preferably in an amount of about 20 %, all weights based on the total weight of the composition.

**[0013]** The compositions in the form of tablets of the present disclosure comprise 1 to 5% by weight of colloidal silicon dioxide in addition to a disintegrant as defined above. Colloidal silicon dioxide may be obtained commercially available as Aerosil®. Colloidal silicon dioxide, is included in the composition of this invention in an amount from 1 to 5 % of the total weight of the composition, preferably in an amount of 2 to 5 % of the total weight of the composition. More preferably, the composition comprises 2 to 4 % and still more preferably 2.5 to 3.5 % of colloidal silicon dioxide based on the total weight of the composition. Most preferably the composition comprises about 3 % of colloidal silicon dioxide by weight.

**[0014]** Preferably, a mixture of colloidal silicon dioxide and crosslinked polyvinylpyrrolidone, may be used e.g. in a ratio of from 1:1 (such as from 1:3) to 1:50 (such as from 1:10).

**[0015]** The macrolide used in the solid dispersion of this disclosure is 40-O-(2-hydroxyethyl)-rapamycin as described in WO94/09010.

**[0016]** Numbering of rapamycin derivatives as used herein refers to the structure disclosed as Formula A at page 4 of PCT international patent application WO 96/13273.

**[0017]** The macrolide 40-O-(2-hydroxyethyl)-rapamycin is preferably present in the composition in an amount of about 0.01 to about 30 %, more preferably 0.1 to 20% by weight based on the total weight of the composition. In particular 40-O-(2-hydroxyethyl)-rapamycin, may be present in the composition in an amount of 0.1 % by weight.

**[0018]** The macrolide used in this disclosure, may be in crystalline or amorphous form prior to formation of the solid dispersion. An advantage, therefore, of this invention is that the macrolide need not be crystalline. Thus, the macrolide may be used directly in combination, for example with a solvent, and does not have to be isolated in advance. Another advantage of the disclosure is that dissolution rates of the solid dispersion are higher than dissolution rates found for a crystalline macrolide or an amorphous macrolide in a simple mixture.

**[0019]** The carrier medium for the preparation of the solid dispersion preferably comprises a carrier, e.g. a water-soluble polymer, for example one or a mixture of the following polymers may be used:

- hydroxypropylmethylcellulose (HPMC). Good results may be obtained using HPMC with a low apparent viscosity, e.g. below 100 cps as measured at 20°C for a 2 % by weight aqueous solution, e.g. below 50 cps, preferably below 20 cps, for example HPMC 3 cps. HPMC is well-known and described, for example, in the Handbook of Pharmaceutical Excipients, pub. Pharmaceutical Society of Great Britain and American Pharmaceutical Association, 1994, pp. 229 to 232, the contents of which are incorporated herein by reference. HPMC, including HPMC 3 cps, is available commercially under the name Pharmacoat® 603 from the Shinetsu company;
- hydroxypropylmethylcellulose phthalate (HPMCP), e.g. as commercially available as HPMCP HP50 or HPMCP HP55;
- polyvinylpyrrolidone (PVP), e.g. PVP K30 or PVP K12. PVP is available commercially, for example, as Povidone®, (Handbook of Pharmaceutical Excipients, p. 392-399) from the BASF company. A PVP having an average molecular weight between about 8,000 and about 50,000 Daltons is preferred, e.g. PVP K30;
- poly(meth)acrylates, e.g. a copolymer which is resistant to gastric juice and soluble in intestinal juices, e.g. a copolymer formed from monomers selected from the group consisting of methacrylic acid, methacrylic acid esters, acrylic acid and

acrylic acid esters, such as those known and commercially available as Eudragit® from Röhm Pharma GmbH. An especially preferred polymer is the 1:1 or 1:2 copolymer formed from monomers selected from the group consisting of methacrylic acid and methacrylic acid lower alkyl esters, such as the 1:1 or 1:2 copolymer formed from methacrylic acid and methyl methacrylate. The 1:1 copolymers are available as Eudragit® L, the 1:2 copolymers are available as Eudragit® S. A particularly preferred polymer is the 1:1 copolymer of methacrylic acid and acrylic acid ethyl ester, commercially as Eudragit® L 100-55;

- hydroxypropylcellulose (HPC) or a derivative thereof. Examples of HPC derivatives include those having low dynamic viscosity in aqueous media, e.g. water, e.g. below about 400 cps, e.g. below 150 cps as measured in a 2 % aqueous solution at 25°C. Preferred HPC derivatives have a low degree of substitution, and an average molecular weight below about 200,000 Daltons, e.g. between 50,000 and 150,000 Daltons. Examples of HPC available commercially include Klucel® LF, Klucel® EF and Klucel® JF from the Aqualon company; and Nisso® HPC-L available from Nippon Soda Ltd;
- a polyethylene glycol (PEG). Examples include PEGs having an average molecular weight between 1000 and 9000 Daltons, e.g. between about 1800 and 7000, for example PEG 2000, PEG 4000, or PEG 6000 (Handbook of Pharmaceutical Excipients, p. 355-361);
- a saturated polyglycolised glyceride, available for example, as Gelucire®, e.g. Gelucire® 44/14, 53/10, 50/13, 42/12, or 35/10 from the Gattefossé company; or
- a cyclodextrin, for example a  $\beta$ -cyclodextrin or an  $\alpha$ -cyclodextrin. Examples of suitable  $\beta$ -cyclodextrins include methyl- $\beta$ -cyclodextrin; dimethyl- $\beta$ -cyclodextrin; hydroxypropyl- $\beta$ -cyclodextrin; glycosyl- $\beta$ -cyclodextrin; maltosyl- $\beta$ -cyclodextrin; sulfo- $\beta$ -cyclodextrin; a sulfo-alkylethers of  $\beta$ -cyclodextrin, e.g. sulfo-C<sub>14</sub>-alkyl ethers. Examples of  $\alpha$ -cyclodextrins include glucosyl- $\alpha$ -cyclodextrin and maltosyl- $\alpha$ -cyclodextrin.

**[0020]** The carrier medium of the solid dispersion is present in an amount of, e.g., 0.1 to 99.99% by weight, for example 0.1 to 99.9 %, e.g. 1 to 95 %, e.g. 5 to 95 %, e.g. 10 to 90 % based on the total weight of the solid dispersion.

**[0021]** In one embodiment of this disclosure, the solid dispersion composition comprises 2% by weight of rapamycin or a derivative thereof, e.g. 40-O-(2-hydroxyethyl)-rapamycin, and 80 % by weight HPMC 3 cps.

**[0022]** The carrier medium for the preparation of the solid dispersion may further comprise one or a combination of a water-soluble or water-insoluble sugar or other acceptable carrier or filler such as saccharose, lactose, amylose, dextrose, mannitol, inositol, and the like, preferably lactose; or microcrystalline cellulose, e.g. commercially available as Avicel®, Pharmacel®, Emcocell®, and Vivapur®, from FMC Corporation (Handbook of Pharmaceutical Excipients, p. 84-87). Preferably, lactose may be used.

**[0023]** A filler, if present, may be generally present in an amount of up to about 50 % by weight, e.g. from about 0.01 to about 50 %, e.g. from about 0.5 to about 40 %, preferably from about 5 to about 35 %, in particular about 20 %, based on the total weight of the solid dispersion.

**[0024]** The carrier medium may further comprise one or more surfactants, for example a nonionic, ionic, or amphoteric surfactant. Examples of suitable surfactants include:

- polyoxyethylene-polyoxypropylene co-polymers and block co-polymers, commercially available as Pluronic® or Poloxamer®, e.g. as described in H. Fiedler, "Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete", Editio Cantor Verlag Aulendorf, Aulendorf, 4th revised and expanded edition (1996). A preferred polyoxyethylene-polyoxypropylene block co-polymer is Poloxamer® 188, commercially available from the BASF company;
- ethoxylated cholesterins, commercially available as Solulan®, for example Solulan® C24, from the Amerchol company;
- vitamin derivatives, e.g. vitamin E derivatives such as tocopherol polyethylene glycol succinate (TPGS), available from the Eastman company;
- sodium dodecylsulfate or sodium laurylsulfate;
- a bile acid or salt thereof, for example cholic acid, glycolic acid or a salt, e.g. sodium cholate; or
- lecithin, e.g. soy bean phospholipid, e.g. commercially available as Lipoid® S75 from Lipoid; or egg phospholipid, e.g. as commercially available as Phospholipon® 90 from Nattermann.

**[0025]** If present, the surfactant(s) may generally be present in an amount from about 0.01 % to about 30 % by weight, e.g. 1 to 20 %, e.g. 1 to 15%, all weights based on the weight of the solid dispersion. Applicants have obtained good results using

surfactant-free solid dispersions.

**[0026]** In another embodiment, the carrier medium for the preparation of the solid dispersion may comprise further additives or ingredients, e.g. an antioxidant and/or a stabilizer for example, in an amount of up to about 5 % by weight, for example about 0.05 to 5 % by weight, e.g. 0.05 to 1 %, in particular about 0.2 %, all weights based on the total weight of the solid dispersion composition. Examples of antioxidants include butylated hydroxytoluene (BHT), butyl hydroxy anisole (BHA), DL- $\alpha$ -tocopherol, propyl gallate, ascorbyl palmitate, and fumaric acid. Preferably, butylated hydroxytoluene may be used. Malonic acid may be an appropriate stabiliser.

**[0027]** 40-O-(2-hydroxyethyl)-rapamycin may be especially admixed with a stabilizer e.g. butylated hydroxytoluene, e.g. in a ratio of from 5:1. to 20:1.

**[0028]** The carrier medium may further include antimicrobial agents, enzyme inhibitors, and preserving agents.

**[0029]** In another aspect, the present disclosure relates to a process for producing a 40-O-(2-hydroxyethyl)-rapamycin containing dispersible tablets, comprising preparing a 40-O-(2-hydroxyethyl)-rapamycin solid dispersion and mixing the 40-O-(2-hydroxyethyl)-rapamycin solid dispersion with a disintegrant and colloidal silicon dioxide wherein the composition comprises 1 to 5% colloidal silicon dioxide by weight to form the pharmaceutical composition and compressing the pharmaceutical composition to form the dispersible tablets.

**[0030]** In the above process, the 40-O-(2-hydroxyethyl)-rapamycin solid dispersion is first prepared. The term solid dispersion as used herein means a preparation in which the macrolide is in an amorphous or substantially amorphous form and is dispersed in a carrier medium. For instance, the solid dispersion may be a co-precipitate or co-evaporate of the macrolide with the carrier medium. The solid dispersion may be a composition which is adapted for further processing to an administrable formulation.

1. A. In one embodiment, the solid dispersion may be obtained by dissolving or suspending the macrolide and carrier medium, e.g. comprising a water-soluble polymer, a filler and an antioxidant, in a solvent or solvent mixture. The solvent may be a single solvent or mixture of solvents, and the order of dissolution and suspension of the macrolide with the carrier medium in the solvent may be varied. Solvents suitable for use in preparing the solid dispersion may be organic solvents such as an alcohol, for example methanol, ethanol, or isopropanol; an ester, e.g. ethylacetate; an ether, e.g. diethylether; a ketone, e.g. acetone; or a halogenated hydrocarbon, e.g. dichloroethane. Preferably a solvent mixture of ethanol/acetone having a weight ratio of ethanol : acetone of between about 1:10 to about 10:1, e.g. 1:5 to 5:1 may be used. Typically the macrolide and carrier medium are present in a ratio by weight with the solvent of 1:0.1 to 1:20. The solvent may be evaporated and the macrolide co-precipitated with the carrier medium.
2. B. In another embodiment, the solid dispersion may be prepared by melting the carrier medium to form a melt, and combining the melt with the macrolide, e.g. by stirring, optionally in the presence of a solvent or solvent mixture as described herein. The resulting mixture may be granulated with a filler, e.g. lactose or mannitol.
3. C. In another embodiment the solid dispersion may be prepared by dissolving or suspending the macrolide and carrier medium in a solvent or solvent mixture as described above, and granulating the resulting solution/dispersion with a filler, e.g. lactose.
4. D. The solid dispersion may be prepared by spray-drying techniques as described, for example, in Theory and Practice of Industrial Pharmacy, Lachmann et al., 1986. A solution/dispersion of the macrolide and carrier medium in a solvent or solvent mixture as described above is dispersed through a nozzle into a chamber maintained at, e.g. 20 to 80°C, and a spraying pressure of e.g. 3 bar. The solvent is evaporated through the nozzle and finely dispersed particles are collected.
5. E. In a further embodiment the solid dispersion may be prepared by spray granulating the solution/dispersion of the macrolide and carrier medium in a solvent or solvent mixture as described above onto a filler, e.g. lactose, or microcrystalline cellulose, or a mixture thereof, in a fluid bed.

**[0031]** In accordance with the present disclosure, the macrolide-containing solid dispersion as described above is further processed to a pharmaceutical composition in the form of a dispersible tablet. The dispersible tablet preferably has a disintegration time of 3 minutes or less.

**[0032]** In an alternative aspect of the disclosure, the solid dispersion composition as described above may be further processed to a rapidly disintegrating powder or granules which may be filled into e.g. sachets or gelatin capsules.

**[0033]** The resulting residues of each of the processes A to B described above may be sieved and milled to particles, e.g. having

a mean particle size of less than about 0.9 mm, e.g. less than about 0.8 mm, for example less than about 350 microns. Preferably the particle size is at least about 5 microns, e.g. about 200 to 300 microns.

**[0034]** The (milled) solid dispersion may be combined with colloidal silicon dioxide, one or more disintegrants such as Crospovidone® and other excipients, such as a filler, e.g. lactose, and blended, sieved and combined with a lubricant, e.g. magnesium stearate, blended, and, for example, compressed to obtain a dispersible tablet, or filled into sachets or gelatin capsules.

**[0035]** One or more lubricants, such as magnesium stearate, may further be included in the composition of this invention. Magnesium stearate may be included in an amount from 0.5 to 2 % by weight, preferably, about 0.5 %, all by weights based on the total weight of the composition.

**[0036]** In a particularly preferred embodiment, the pharmaceutical composition further comprises a lubricant and a filler.

**[0037]** It may be advantageous to include one or more sweetening or flavoring agents in the compositions of this invention, e.g. in an amount of about 2.5 or 5 % by weight based on the total weight of the composition.

**[0038]** In another embodiment of the disclosure a water-soluble or water-insoluble sugar or other acceptable filler such as saccharose lactose, or microcrystalline cellulose (e.g., as available as Avicel®, from FMC Corporation) may be included in the compositions of this invention. Preferably lactose, in particular anhydrous lactose, may be used, e.g. in an amount of up to about 90 % by weight, e.g. 20 to 80 %, preferably from about 50 to about 72 %, all weights based on the total weight of the composition.

**[0039]** The rapidly disintegrating compositions of this disclosure are administered and formulated in the form of a tablet. Whereas hereinafter the compositions are described with particular reference to tablets other types of dosage forms may be produced and are encompassed within the scope of this invention.

**[0040]** Tablets may be produced from the compositions of the present disclosure using any suitable apparatus or procedure. Typically a tablet press is used to compress the compositions. Varying amounts of the compositions may be compressed in order to produce tablets of different weights. In preferred embodiments, 50 to 500 mg of the composition is compressed into each tablet. More preferably, tablets are produced having a weight of about 100 mg or about 250 mg.

**[0041]** The force used to compress the present compositions may be varied in order to vary the hardness and disintegration time of the resulting tablets. Use of a higher compression force results in harder tablet with a longer disintegration time. For a dispersible tablet, it is important that the disintegration time is sufficiently short so that the tablet can be conveniently dispersed in an aqueous solution before consumption. Therefore it is necessary to select an appropriate compression force in order to achieve the desired disintegration time.

**[0042]** However, it is also important that tablets have a sufficient degree of mechanical strength. The present compositions are advantageous because for a given compression force, the resultant tablets disintegrate more rapidly in an aqueous solution than prior art tablets. Even so, the tablets of the present disclosure retain a sufficient degree of hardness. In order to achieve a dispersible tablet having a sufficiently short disintegration time using prior art formulations, a very low compression force would need to be used. This would produce a tablet having inadequate hardness and mechanical properties.

**[0043]** It is also important to take into account the weight of the tablet when selecting a compression force. The required level of hardness is lower for a smaller tablet, and a lower compression force is typically used. A skilled person could select an appropriate compression force in order to achieve the desired disintegration time for a tablet of particular size.

**[0044]** In one aspect the dispersible tablets described herein have a high porosity showing rapid disintegration in an aqueous solution such as water. The rapid dispersibility may be observed in standard tests. The disintegration time is preferably measured according the standard test for dispersible tablets described in European Pharmacopoeia 4.1, page 2435, (2002) in combination with European Pharmacopoeia 4, page 191, 2.9.1 (2002). This test examines the disintegration time of tablets in water at 15 to 25 °C.

**[0045]** The dispersion may be observed visually. Disintegration is considered to be achieved when no residue remains on the screen, or if there is residue, it consists of a soft mass having no palpably firm, unmoistened core, or only fragments of coating (tablets), or only fragments of shell (capsules) remain on the screen.

**[0046]** The tablets of the present disclosure preferably have a disintegration time of 3 minutes or less, when measured according

to the above test. More preferably the disintegration time is 2 minutes or less, still more preferably the disintegration time is 90 seconds or less and most preferably the disintegration time is 30 to 65 seconds.

**[0047]** The hardness, or resistance to crushing, of tablets according to the present disclosure may be determined by standard tests. Tablet hardness is preferably determined according to the standard test specified at European Pharmacopoeia 4, page 201, 2.9.8 (2002). A device such as a Kraemer® 3S tablet testing device may be used. This test determines the resistance to crushing of tablets, measured by the force needed to disrupt them by crushing.

**[0048]** The hardness of the tablets of the present disclosure varies according to the weight and diameter of the tablets and the compression force. For a 200 to 300 mg tablet, for example a 250 mg tablet, having a diameter of approximately 9 mm, the hardness is preferably 35 to 80 N. In order to achieve such a hardness, a compression force of 8 to 11 kN is preferably applied. For a 50 to 150 mg tablet, for example a 100 mg tablet, having a diameter of approximately 7mm, the hardness is preferably 25 to 60 N, and may be achieved by applying a compression force of 7 to 9 kN. For other tablet weights and diameters, the preferred hardness varies.

**[0049]** Thus the advantageous properties of the present compositions may be demonstrated by the hardness and disintegration time of tablets produced from such compositions. Accordingly, in a preferred embodiment the present disclosure relates to a pharmaceutical composition as defined above, wherein 250 mg of the composition, when compressed using a compression force of 8 to 11kN with a 9 mm die and standard flat punches, forms a tablet having a hardness of 35 to 80 N. Preferably the composition is compressed using a tablet press such as a Fette® PT 2080 Rotary tablet press. The hardness is measured by the standard procedure mentioned above, for example using a Kraemer® 3S tablet testing device. The pharmaceutical composition is more preferably such that 250 mg of the composition, when compressed using a compression force of 9.5 kN with a 9 mm die and standard flat punches, forms a tablet having a hardness of 40 to 66 N. The disintegration time of a tablet formed in such a way from the composition is preferably 3 minutes or less, more preferably 90 seconds or less when determined using the test specified above.

**[0050]** In an alternative embodiment, the present disclosure invention relates to a pharmaceutical composition as defined above, wherein 100 mg of the composition, when compressed using a compression force of 7 to 9 kN with a 7 mm die and standard flat punches, forms a tablet having a hardness of 25 to 60 N. More preferably the pharmaceutical composition is such that 100 mg of the composition, when compressed using a compression force of 8.3 kN with a 7 mm die and standard flat punches, forms a tablet having a hardness of 29 to 53 N. The disintegration time of a tablet formed in such a way from the composition is preferably as given in the preceding paragraph.

**[0051]** The above statements of the disclosure define the pharmaceutical composition in terms of the properties of a particular tablet which may be made from such a composition. However, it is clear that the invention is in no way thereby limited to tablets having such a weight, diameter, or hardness, or only to a production process involving the use of such a compression force. As discussed above, these values may vary for different types of tablet. The above definition is rather given in order to clarify the advantageous intrinsic properties of the present pharmaceutical compositions, which mean that when they are formulated into tablets they afford a rapid disintegration time in combination with a good degree of hardness.

**[0052]** The tablets obtained by the compression method described above may vary in shape and be, for example, round, oval, oblong, cylindrical, flat or curved, or any other suitable shape, and may also vary in size depending on the concentration of the therapeutic agents.

**[0053]** In a preferred embodiment of the disclosure tablets obtained by the compression method described above are round and flat. The edges of the tablets may be bevelled or rounded.

**[0054]** The compositions of this disclosure may be administered to a patient, such as a child, in form of a rapidly disintegrating composition, e.g. a dispersible tablet, which composition may be administered together with a liquid, e.g. an aqueous medium such as water. Upon addition of the liquid to the formulation, e.g. a unit dosage form or dosage such as a tablet, e.g. on a spoon, the composition, disintegrates rapidly to form a dispersion, e.g. in less than 3 minutes, preferably less than 90 seconds, more preferably between 30 and 65 seconds, thus allowing convenient administration. For administration to children, a sweetener or other additives may be added to the aqueous medium in which the tablet is dispersed, in order to mask any unpleasant taste and to make the dispersion more palatable.

**[0055]** When required, the compositions of the disclosure in form of a rapidly disintegrating composition are preferably compounded in unit dosage form, e.g. as a dispersible tablet, capsule, granules or powder, preferably as a dispersible tablet.



Where the composition is in unit dosage form, each unit dosage form comprising rapamycin or a derivative thereof will suitably contain between 0.05 mg and 10 mg of the drug substance, more preferably between 0.1 and 5 mg; for example 0.1 or 0.25 mg. Such tablets are suitable for administration 1 to 5 times daily depending upon the particular purpose of therapy, the phase of therapy and the like.

**[0056]** The compositions of the disclosure may show good stability characteristics as indicated by standard stability trials, for example having a shelf life stability of up to one, two or three years, and even longer.

**[0057]** The particles or granules obtained by any of the processes A to E as described above may be coated, for example using an enteric coating. Suitable coatings may comprise cellulose acetate phthalate, hydroxypropylmethylcellulose phthalate; a polymethacrylic acid polymer, e.g. Eudragit® L, S; or hydroxypropylmethyl cellulose succinate.

**[0058]** The tablets obtained by the compression method described above may furthermore be coloured, and the tablets marked so as to impart an individual appearance and to make them instantly recognizable. The use of dyes can serve to enhance the appearance as well as to identify the compositions. Dyes suitable for use in pharmacy typically include carotinoids, iron oxides, and chlorophyll. Preferably, the tablets of the invention are marked using a code.

**[0059]** Procedures which may be used are known in the art, e.g. those described in L. Lachman et al. The Theory and Practice of Industrial Pharmacy, 3rd Ed, 1986, H. Sucker et al, Pharmazeutische Technologie, Thieme, 1991, Hagers Handbuch der pharmazeutischen Praxis, 4th Ed. (Springer Verlag, 1971) and Remington's Pharmaceutical Sciences, 13th Ed., (Mack Publ., Co., 1970) or later editions.

**[0060]** The pharmaceutical compositions of the disclosure are useful for the same indications as the macrolide, 40-O-(2-hydroxy)ethyl rapamycin. The pharmaceutical compositions comprising 40-O-(2-hydroxy)ethyl rapamycin are particularly useful for:

1. a) treatment or prevention of cell, tissue or organ allo- or xeno-transplant rejection, for example for heart, lung, combined heart-lung, liver, kidney, bowel, pancreatic, insulin producing cells, skin or corneal transplants. The pharmaceutical compositions are also indicated for the prevention of graft-versus-host disease, such as sometimes occurs following bone marrow transplantation;
2. b) treatment or prevention of autoimmune disease and of inflammatory conditions, in particular inflammatory conditions with an etiology including an autoimmune component such as arthritis (for example, rheumatoid arthritis, arthritis chronic progrediente and arthritis deformans) and rheumatic diseases. Specific autoimmune diseases for which the compounds of the disclosure may be employed include, autoimmune hematological disorders (including e.g. hemolytic anaemia, aplastic anaemia, pure red cell anaemia and idiopathic thrombocytopenia), systemic lupus erythematosus, polychondritis, sclerodoma, Wegener granulomatosis, dermatomyositis, chronic active hepatitis, myasthenia gravis, psoriasis, Steven-Johnson syndrome, idiopathic sprue, autoimmune inflammatory bowel disease (including, e.g., ulcerative colitis and Crohn's disease) endocrine ophthalmology, Graves disease, sarcoidosis, multiple sclerosis, primary billiary cirrhosis, juvenile diabetes (diabetes mellitus type I), uveitis (anterior and posterior), keratoconjunctivitis sicca and vernal keratoconjunctivitis, interstitial lung fibrosis, psoriatic arthritis, glomerulonephritis (with and without nephrotic syndrome, e.g. including idiopathic nephritic syndrome or minimal change nephropathy) and juvenile dermatomyositis;
3. c) treatment or prevention of asthma
4. d) treatment or prevention of chronic graft rejection or restenosis;
5. e) treatment of cancer, hyperproliferative skin disorder, and the like;
6. f) treatment of infections, e.g. fungal infections;
7. g) treatment or prevention of inflammation, especially in potentiating the action of steroids;

**[0061]** The pharmaceutical compositions of the disclosure comprising 40-O-(2-hydroxyethyl)-rapamycin are particularly useful, for example, in the treatment of inflammatory and hyperproliferative skin diseases and of cutaneous manifestations of immunologically-mediated diseases. More specifically, the compositions are useful as antiinflammatory and as immunosuppressant and antiproliferative agents for use in the prevention and treatment of inflammatory conditions and of conditions requiring immunosuppression, such as

1. a) the prevention or treatment of
  - rejection of organ or tissue transplantation, e.g. of heart, kidney, liver, bone marrow and skin,
  - graft-versus-host disease, such as following bone marrow grafts,
  - autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple

- sclerosis, Myasthenia gravis, diabetes type I, and uveitis,
- cutaneous manifestations of immunologically-mediated illnesses;
2. b) the treatment of inflammatory and hyperproliferative skin diseases, such as psoriasis, atopic dermatitis, contact dermatitis and further eczematous dermatitises, seborrhoeic dermatitis, Lichen planus, Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias, Lupus erythematosus, and acne; and
  3. c) Alopecia areata.

[0062] In a further aspect, the present disclosure provides a composition as defined above, for use as an immunosuppressant, e.g. in the treatment or prevention of one of the above mentioned diseases or disorders.

[0063] The dispersible tablets of this disclosure may be dispersed before ingestion in e.g. 20 to 50 ml water with stirring.

[0064] The exact amount of the compositions to be administered depends on several factors, for example the desired duration of treatment and the rate of release of the macrolide.

[0065] The here mentioned compositions exhibit especially advantageous properties when administered orally; for example in terms of consistency and level of bioavailability obtained in standard bioavailability trials. These trials are performed in animals, e.g. rats or dogs, or healthy volunteers.

[0066] Pharmacokinetic parameters, for example absorption and blood levels, also become surprisingly more predictable and problems in administration with erratic absorption may be eliminated or reduced. Additionally the compositions are effective with tenside materials, for example bile salts, being present in the gastro-intestinal tract.

[0067] The utility of the pharmaceutical compositions can be observed in standard clinical tests in, for example, known indications of active agent dosages giving equivalent blood levels of active agent; for example using dosages in the range of 0.01 mg to 5 mg/kg body weight per day, e.g. 0.5 to 5 mg/kg body weight per day of rapamycin or a derivative thereof in mammals, e.g. children (e.g. below 12 years and e.g. at least 3 years) or elderly, and in standard animal models; or for example using dosages in the range of 1 mg to 1000 mg, e.g. 2.5 to 1000 mg, preferably 10 to 250 mg, per day of an ascomycin for a 75 adult and in standard animal models. The increased bioavailability of the drug substance provided by the compositions can be observed in standard animal tests and in clinical trials.

[0068] Following is a description, by way of example only, of pharmaceutical composition of the invention.

#### **Example 1**

##### ***Preparation of a solid dispersion***

[0069] A 2 % solid dispersion (SD) composition is prepared containing the following ingredients:

	wt. (g)	wt. %
40-O-(2-hydroxyethyl)-rapamycin	0.04	2.0
Butylated hydroxytoluene	0.004	0.2
HPMC 3 cps	1.6	80.0
Lactose, monohydrate (200 mesh)	0.356	17.8
Total	2.0	100

[0070] The composition is prepared by (i) mixing the 40-O-(2-hydroxyethyl)-rapamycin and butylated hydroxytoluene (ii) dissolving the mixture obtained in (i) in an ethanol/acetone mixture, (iii) adding the HPMC and the lactose, (iv) homogenously dispersing the mixture obtained in step (iii), and (v) removing the solvents by evaporation. The resulting residue is dried, sieved and milled.

**Preparation of a pharmaceutical composition**

[0071] A pharmaceutical composition (containing the solid dispersion described above) is prepared containing the following ingredients (in parts by weight):

40-O-(2-hydroxyethyl)-rapamycin SD 2%	5
Crospovidone®	20
Aerosil®	3
Magnesium stearate	0.5
Lactose, anhydrous	71.5
Total	100

[0072] The composition is prepared by (i) blending the solid dispersion (SD), lactose, Crospovidone® and Aerosil®, (ii) sieving (0.8 mm), and blending, (iii) adding sieved (0.8 mm) magnesium stearate and blending.

**Preparation of a dispersible tablet**

[0073] A dispersible tablet is obtained by tableting the mixture obtained in step (iii). 250 mg of the pharmaceutical composition is compressed with a Fette® PT 2080 Rotary tablet press using a compression force of 10.5 kN with a 9 mm die and standard flat punches. The hardness of the resulting tablet is then assessed by measuring the force required to crush the tablet using a Kraemer 3S tablet testing device. The hardness of tablets manufactured under these conditions was between 35 and 79 N. The disintegration time of such tablets was 0.4 to 1.4 minutes (24 to 84 seconds).

**Example 2**

[0074] A pharmaceutical composition was prepared as described above. A dispersible tablet was prepared by compressing 100 mg of the pharmaceutical formulation with a Fette® PT 2080 Rotary tablet press using a compression force of 7.5 kN with a 7 mm die and standard flat punches. The hardness of tablets manufactured under these conditions was from 25 to 79 N. The disintegration time of such tablets was 1.1 to 1.7 minutes (66 to 102 seconds).

[0075] The examples above illustrate compositions and tablets useful for example in the prevention of transplant rejection or for the treatment of autoimmune disease, on administration of from 1 to 5 unit dosages/day at a dose of between 0.01 to 5 mg/kg body weight per day.

[0076] The examples are described with particular reference to 40-O-(2-hydroxyethyl)-rapamycin. However, in further examples the method described in examples 1 and 2 is repeated except that 40-O-(2-hydroxyethyl)-rapamycin is replaced by an alternative macrolide. The alternative macrolide may be any rapamycin derivative or ascomycin derivative mentioned above, for instance FK-506 or 33-epi-chloro-33-desoxy-ascomycin. Tablets comprising such alternative macrolides have a hardness and disintegration time which is similar to that given above for 40-O-(2-hydroxyethyl)-rapamycin containing tablets, and are also useful as immunosuppressants.

**REFERENCES CITED IN THE DESCRIPTION**

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US3929992A](#) [0003]
- [WO9402136A](#) [0003] [0003]
- [US5258389A](#) [0003]
- [WO9409010A](#) [0003] [0015]
- [WO9205179A](#) [0003]
- [US5118677A](#) [0003]
- [US5118678A](#) [0003]
- [US5100883A](#) [0003]
- [US5151413A](#) [0003]
- [US5120842A](#) [0003]
- [WO9311130A](#) [0003]
- [WO9402385A](#) [0003]
- [WO9514023A](#) [0003]
- [US5256790A](#) [0003]
- [WO9602441A](#) [0004]
- [WO9703654A](#) [0005]
- [WO9613273A](#) [0016]

Non-patent literature cited in the description

- **KESSELER, H. et al.** Helv. Chim. Acta, 1993, vol. 76, 117- [0003]
- **MCALPINE, J.B. et al.** J. Antibiotics, 1991, vol. 44, 688- [0003]
- **SCHREIBER, S.L. et al.** J. Am. Chem. Soc., 1991, vol. 113, 7433- [0003]
- Handbook of Excipients 143-144 [0012]
- Handbook of Pharmaceutical Excipients Pharmaceutical Society of Great Britain 1994 0000229-232 [0019]
- Handbook of Pharmaceutical Excipients 392-399 [0019]
- Handbook of Pharmaceutical Excipients 355-361 [0019]
- Handbook of Pharmaceutical Excipients 84-87 [0022]
- **H. FIEDLER** Lexikon der Hilfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete Editio Cantor Verlag 1996 0000 [0024]
- European Pharmacopoeia 4.1, 2002, 2435- [0044]
- European Pharmacopoeia, 2002, vol. 4, 191- [0044]
- European Pharmacopoeia, 2002, vol. 4, 201- [0047]
- **L. LACHMAN et al.** The Theory and Practice of Industrial Pharmacy 1986 0000 [0059]
- **H. SUCKER et al.** Pharmazeutische Technologie Thieme 1991 0000 [0059]
- Hagers Handbuch der pharmazeutischen Praxis Springer Verlag 1971 0000 [0059]
- Remington's Pharmaceutical Sciences Mack Publ., Co. 1970 0000 [0059]

## FARMACEUTISKE SAMMENSÆTNINGER OMFATTENDE KOLLOIDT SILICIUMDIOXID

## PATENTKRAV

1. Farmaceutisk sammensætning i form af en dispergerbar tablet, der omfatter en fast 40-O-(2-hydroxy)ethyl-rapamycindispersion, et disintegrationsmiddel og kolloidt siliciumdioxid, hvor  
5 sammensætningen omfatter 1 til 5 vægt-% kolloidt siliciumdioxid.
2. Farmaceutisk sammensætning ifølge krav 1, hvor disintegrationsmidlet er natriumstivelsesglycolat eller croscarmelosenatrium.
3. Farmaceutisk sammensætning ifølge krav 1 eller 2, hvor 250 mg af sammensætningen, når den komprimeres ved anvendelse af en kraft på 8 til 11 kN med en 9 mm presse og flade standardudstansninger,  
10 danner en tablet, der har en hårdhed på 35 til 80 N og en disintegrationstid på 3 minutter eller mindre.
4. Farmaceutisk sammensætning ifølge et hvilket som helst af de foregående krav, hvor tabletten har en disintegrationstid på 90 sekunder eller mindre.
5. Farmaceutisk sammensætning ifølge et hvilket som helst af de foregående krav til anvendelse som et immunsuppressivt stof.
- 15 6. Fremgangsmåde til fremstilling af en dispergerbar 40-O-(2-hydroxy)ethyl-rapamycin-holdig tablet, hvilken fremgangsmåde omfatter fremstilling af en fast 40-O-(2-hydroxy)ethyl-rapamycindispersion, blanding af den faste 40-O-(2-hydroxy)ethyl-rapamycindispersion med et disintegrationsmiddel og kolloidt siliciumdioxid, hvor sammensætningen omfatter 1 til 5 vægt-% kolloidt siliciumdioxid for at danne en farmaceutisk sammensætning, og komprimering af den farmaceutiske sammensætning for at danne den  
20 dispergerbare tablet.
7. Fremgangsmåde ifølge krav 6, hvor disintegrationsmidlet er natriumstivelsesglycolat eller croscarmelosenatrium.